Position in SVTR
Snapshot 2026-10-29- Startup SignalsRankedof 2,186new
- Life SciencesRankedof 230
- AI for ScienceRankedof 108
- Drug DiscoveryRankedof 62
About
Omabit builds an AI platform that turns pharma R&D data (genomic, clinical, PK, RNA-seq) into answers by running analyses, cross-checking them against published research and writing them up, serving clinical development, biomarker, translational and biostatistics teams and compressing ~3-month analyses to about a day.
Full tier & rationale — an SVTR Intelligence benefit
Capital graph
Investor· 1
Founders / team· 3
Funding history
- 2026-10-27Seed$2M
Investors · Bright VenturesSource · omabit.com ↗
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- Omabit
Omabit builds an AI platform that turns pharma R&D data (genomic, clinical, PK, RNA-seq) into answers by running analyses, cross-checking them against published research and writing them up, serving clinical development, biomarker, translational and biostatistics teams and compressing ~3-month analyses to about a day.
Seed · $2M · 2026-10
$2M
United States
BusinessLatest roundTotal raisedDate- 10x Science
AI analysis of experimental data to identify and characterize proteins for drug development
Seed · $5M · 2026-04
$5M - Cheiron
AI-native "drug program operating system" for biopharma teams that models drug R&D programs on a life sciences knowledge graph
Seed · $8M · 2026-07
$8M - Topos Bio
AI-driven drug discovery targeting intrinsically disordered proteins
Seed · $107M · 2026-01
$107M
China
BusinessLatest roundTotal raisedDate- ATLATL Innovation Center
R&D infrastructure and incubation for early-stage biopharma: shared labs, resident scientists and project management, GMP process optimization, preclinical pharmacology and toxicology, plus an AI drug screening module, for biopharma startups, university and institute spinout teams and multinational pharma
— - Deep Pharma
AI-driven drug discovery and clinical development platform
Series D+ · $200M · 2026-03
$200M - BioGeometry
Generative AI protein/antibody design platforms (GeoFlow, GeoBiologics) and closed-loop dry-wet lab drug discovery
Series A · $100M · 2026-10
$100M
Europe
BusinessLatest roundTotal raisedDate- DaltonTx
Adaptive AI discovery platform for drug development
Seed · $6M · 2025-09
$6M - Amply
AI-accelerated development of gene-silencing therapies for aggressive cancers and inhaled antimicrobials for drug-resistant infections
Seed · $4M · 2025-05
$4M - OutSee
AI analysis of individual genomes to predict disease biology and help drug developers find new targets
Seed · $2M · 2025-06
$2M
Other / unspecified
BusinessLatest roundTotal raisedDateConfirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
Y Combinator
40 Life Sciences deals in the last 24 months · 28 at a nearby stage · 33 in Silicon Valley
Request intro →General Catalyst
40 Life Sciences deals in the last 24 months · 19 at a nearby stage · 36 in Silicon Valley
Request intro →Andreessen Horowitz
24 Life Sciences deals in the last 24 months · 11 at a nearby stage · 22 in Silicon Valley
Request intro →Khosla Ventures
21 Life Sciences deals in the last 24 months · 7 at a nearby stage · 20 in Silicon Valley
Request intro →Thrive Capital
18 Life Sciences deals in the last 24 months · 3 at a nearby stage · 15 in Silicon Valley
Request intro →Lightspeed
17 Life Sciences deals in the last 24 months · 5 at a nearby stage · 15 in Silicon Valley
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.